these results suggest the potential value of relatively high doses of d2 dopamine agonists ( such as bromocriptine ) in the first line treatment of parkinson 's disease : however , their use can be limited by their decrease of effectiveness after several years and/or the occurrence of severe neuropsychiatric side-effects .
C0006230
bromocriptine
C0030567
parkinson 's disease